Pain Management Drugs Market - Global Forecast, 2022 - 2028

Pain Management Drugs Market - Global Forecast, 2022 - 2028

Pain management drugs are prescribed in serious to mild pain conditions such as back pain, neck pain, and pain from cancer. Pain management drugs market is highly lucrative due to low availability of alternative drug therapies for treatment of pain. Drug manufacturers are introducing effective generic version in various dosage forms, which is driving the market growth. Chronic pain is one of the highly prevalent pain disorders, which is primarily treated by these medications. The medical management of pain diseases is patient specific and is highly dependent on individual patients’ symptoms.
Market Dynamics
The global pain management drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs such as OxyContin, Opana ER, and Celebrex have lost patent protection due to which generic manufacturers have developed generic version with product variations fostering growth of the pain management drugs market. Continuous requirement of the medication coupled with easy availability is expected to boost the adoption of pain drugs over the forecast period. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as cancer (leading to cancer pain) are fueling growth of the pain management drugs market. However, life threatening side effects associated with these medications, as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the pain management drugs market.
Key features of the study:
This report provides in-depth analysis of pain management drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pain management drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global pain management drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pain management drugs market
Detailed Segmentation:
Global Pain Management Drugs Market, by Drug Class:
Opioids
NSAIDs
Anticonvulsants
Antidepressants
Others
Global Pain Management Drugs Market, by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Pain Management Drugs Market, by Region:
North America
By Drug Class:
Opioids
NSAIDs
Anticonvulsants
Antidepressants
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Class:
Opioids
NSAIDs
Anticonvulsants
Antidepressants
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Opioids
NSAIDs
Anticonvulsants
Antidepressants
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Class:
Opioids
NSAIDs
Anticonvulsants
Antidepressants
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Rest of Latin America
Middle East
By Drug Class:
Opioids
NSAIDs
Anticonvulsants
Antidepressants
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Opioids
NSAIDs
Anticonvulsants
Antidepressants
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Central Africa
South Africa
North Africa
Company Profiles
Pfizer, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Sanofi S.A.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
Abbott Laboratories
Purdue Pharma L.P.
GlaxoSmithKline Plc
Johnson & Johnson
F. Hoffmann La Roche Ltd.
“*” marked represents similar segmentation in other categories in the respective section.